fx2452
10 Dec 2019
Thoughts on Future Market Cap Turkey arrived just in time for Christmas! So it looks like mild to moderate ED can be cured by a rub! And it took over a decade to reach this conclusion. Am also out.
Ecologist
10 Dec 2019
Thoughts on Future Market Cap Me too
trump53
10 Dec 2019
Thoughts on Future Market Cap The market doesn’t like uncertainty, and that’s what this RNS provides. Input to Phase 3 study input was from Regulators and interested Pharma wanting to know what claims to make and how far those claims could be substantiated. Can’t see pharma being too interested at present, but gives those PDE5 distributors the chance to kill FUM’s ED product off with a low bid, unless they feel they don’t need to bother. From the RNS: “We will provide shareholders with an update on what we believe will be a new simpler and expected lower cost regulatory pathway as soon as possible.†ASAP isn’t fast enough JB.
smashing1
10 Dec 2019
Thoughts on Future Market Cap Best of luck elsewhere Aberdeen. FUM is a pretty uncomfortable roller coaster.
Aberdeen_investor
10 Dec 2019
Thoughts on Future Market Cap I’m out. Good luck to all those that remain.
Ecologist
10 Dec 2019
Thoughts on Future Market Cap I just got a tentative quote at 14.25p to sell but I believe it has fallen through that level
Ecologist
10 Dec 2019
Thoughts on Future Market Cap Let’s not do things simply FUM. What do these results really mean? Either that there is an unexpected active ingredient in Dermasys (and we have just had an amazing stroke of luck) or (my preference) that a good % of ED is in the head and that any old gel when applied with a soft hand would work. Will we be revisiting 6p? Ouch.
markthemango1
10 Dec 2019
Thoughts on Future Market Cap Unusual results today, feel like it’s going to hit the SP hard. Looks like the Dermasys is actually the main cause of getting an erection and not the GTN gel. The results are therefore inconclusive for now with Dermasys being used in the placebo. In the short term this will really hit FUM, can’t see any potential Pharmas investing in this at the moment and funding is going to be an issue, I’d expect another fundraiser soon. In the long term though the potential of this is massive, if Dermasys is the cause of people getting the erections this is great news if they can differentiate it from a palcebo and should be cheaper to get it to market.
Pharmatom
09 Dec 2019
Thoughts on Future Market Cap gettin’ impatient
ZeroV
04 Dec 2019
Thoughts on Future Market Cap It’s a painful wait… I’m amazed at the lack of activity, I m surprised traders haven’t started to try and create movement for their short term gains… either they are scared of getting caught short with news announcement or worried about more offloading prior to news read-out. Given the complete lack of rumours one way or the other suggests that no one in the city is getting excited by this and therefore a deal is a fair bit off being on the table…
Aberdeen_investor
04 Dec 2019
Thoughts on Future Market Cap Jumping ahead of myself but what’s the best strategy for this product? Initially it’ll be prescription so a pharma company is best placed to realise the value. Later on it becomes a consumer health type product so possibly a consumer health type company is best placed to realise the full potential? Perhaps two different licensing agreements for the same territory. One for prescription and one for OTC I think. Not long to go now. If I were a betting man, I’d guess headline data either next week or the week after, so a maximum of a couple of weeks wait time . Good luck all
MRLOLOL
28 Nov 2019
Thoughts on Future Market Cap Behind a paywall sadly, attempted to sign up but wasn’t willing to apply for the trial as the free account doesn’t work.
trump53
28 Nov 2019
Thoughts on Future Market Cap Does anybody have a link to todays 15 page Liberum report please?
Lastemporer
25 Nov 2019
Thoughts on Future Market Cap Pharma is the game for big ups and downs: CCXI - ChemoCentryx, Inc. is up 327% pre market for: The company announces positive topline data from its pivotal phase III ADVOCATE trial for avacopan. The test achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks. Other notes: Significantly reduced glucocorticoid toxicity, significantly improved kidney function compared to glucocorticoid-containing SOC, improved health-related quality of life measures compared to SOC
Lastemporer
25 Nov 2019
Thoughts on Future Market Cap New report out: "A recent report by Trinity Delta projects that lead product MED2005, a breakthrough topical glyceryl trinitrate (GTN) gel treatment for erectile dysfunction in Phase 3 development, has the potential to be a highly differentiated therapy, especially for patients suffering from mild to moderate ED. Headline data expected by the end of 2019 and results are expected to be positive. Read full equity research report by Trinity Delta below." Trinity Delta Futura Medical | Trinity Delta Investment research on Futura Medical, an R&D driven pharma with a novel DermaSys transdermal delivery platform and a Phase III product (MED2005) for erectile dysfunction.
